(4-Ethyl-phenyl)-methanethiol | 7341-27-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-Ethyl-phenyl)-methanethiol
• 英文别名: (4-Ethylphenyl)methanethiol
• CAS: 7341-27-7
• 化学式: C₉H₁₂S
• 分子量: 152.26
• InChiKey: DRNRNRPJNRQTKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (4-Ethyl-phenyl)-methanethiol 在 氢氧化钾 、 三(三甲代甲硅烷基)亚磷酸盐 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.25h， 生成
  参考文献：
  名称：

  Nitroarylhydroxymethylphosphonic acids as inhibitors of CD45

  摘要：

  A series of nitroarylhydroxymethylphosphonic acids was synthesized and evaluated as inhibitors of CD45. It was discovered that both the alpha hydroxy and nitro groups are essential for activity. Potency is enhanced by the addition of a large lipophilic group on the aryl ring adjacent to the phosphonic acid moiety. Kinetics studies have shown that these compounds are competitive inhibitors and thus bind at the active site of this enzyme. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00174-0

文献信息

• TREATMENT AND PREVENTION OF NEUROPATHIC PAIN WITH P2Y14 ANTAGONISTS
  申请人：Saint Louis University

  公开号：US20210024489A1

  公开（公告）日：2021-01-28

  Disclosed herein are methods for treating neuropathic pain in a subject in need thereof. The methods include: administering to a subject in need thereof a therapeutically effective amount of an antagonist of P2Y14.

  本文公开了治疗神经病理性疼痛的方法，包括向需要的受试者施用P2Y14的拮抗剂的治疗有效量。
• [EN] NLRP3 MODULATORS<br/>[FR] MODULATEURS DE NLRP3
  申请人：IFM THERAPEUTICS INC

  公开号：WO2017184735A1

  公开（公告）日：2017-10-26

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonize or partially agonize) NLRP3 and TLR7 and/or TLR8 that are useful, e.g., for treating a condition, disease or disorder in which a decrease in NLRP3 and TLR7 and/or TLR8 activities (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 and TLR7 and/or TLR8 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开涉及化合物（例如化合物或药物可接受的盐，水合物，共晶物或化合物的药物组合物），其调节（例如激动或部分激动）对治疗某种疾病、疾病或紊乱有用，其中NLRP3和TLR7以及/或TLR8的活性降低（例如与抑制或受损的NLRP3和TLR7和/或TLR8信号相关的疾病、疾病或紊乱）对该疾病、疾病或紊乱的病理学和/或症状和/或进展有贡献（例如癌症）的主体（例如人类）。本公开还涉及组合物以及使用和制备它们的其他方法。
• Thiobenzimidazole derivatives
  申请人：Matsumoto Yoshiyuki

  公开号：US20070275995A1

  公开（公告）日：2007-11-29

  The present invention is a thiobenzimidazole derivative represented by the following formula (1) or a medically acceptable salt thereof wherein said thiobenzimidazole derivative and a medically acceptable salt thereof have a potent activity of inhibiting human chymase. Thus, they are potential preventive and/or therapeutic agents clinically applicable to various diseases in which human chymase is involved.

  本发明是一种由以下公式（1）表示的硫代苯并咪唑衍生物或其医学上可接受的盐，其中所述的硫代苯并咪唑衍生物及其医学上可接受的盐具有抑制人类胰蛋白酶的强效活性。因此，它们是潜在的预防和/或治疗剂，可在人类胰蛋白酶参与的各种疾病中进行临床应用。
• Novel copolymers and superoxide dismutase modified with said copolymers
  申请人：KURARAY CO., LTD.

  公开号：EP0314042A2

  公开（公告）日：1989-05-03

  Described are copolymers comprising the copolymer-­constituting units characterized in the claims and having an average molecular weight of 400 to 20,000. Furthermore superoxide dismutase (SOD) derivatives are described which can be obtained by modification with the above copolymers and have a single chemical structure, retain most of the enzymatic activity of SOD and exhibit a much prolonged plasma half-life. Therefore, they are useful as medicinal chemicals.

  所述的共聚物包括权利要求所述的共聚物构成单元，其平均分子量为 400 至 20000。此外，还描述了超氧化物歧化酶（SOD）衍生物，这些衍生物可通过上述共聚物改性获得，具有单一的化学结构，保留了 SOD 的大部分酶活性，并大大延长了血浆半衰期。因此，它们可用作医药化学品。
• Olefin polymerization catalyst and process for producing olefin polymer
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP1081167A1

  公开（公告）日：2001-03-07

  An olefin polymerization catalyst prepared by contacting a specified transition metal compound(A) having a cyclopentadiene type anion skeletons in its molecule with a modified aluminum oxy compound (B) obtained by reacting an aluminum oxy compound(B1) with a compound having a hydroxyl group(B2), and a process for producing an olefin polymer using the olefin polymerization catalyst.

  一种烯烃聚合催化剂，其制备方法是将分子中含有环戊二烯型阴离子骨架的特定过渡金属化合物（A）与铝氧化合物（B1）和具有羟基的化合物（B2）反应得到的改性铝氧化合物（B）接触，以及使用该烯烃聚合催化剂生产烯烃聚合物的工艺。